BioHarvest Sciences welcomes research, which supports VINIA as potentially capable of improving heart function

BioHarvest Sciences Inc revealed that recent research analysis has boosted the case for its VINIA product to aid heart function.

The new research affirmed claims for VINIA red grape powder, according to US Food & Drug Administration (FDA) guidelines for dietary supplements, such as that it prevents lipid oxidation; protects the body by preventing oxidative damage to the cells, and reduces oxidation of LDL cholesterol.

“Cholesterol damages the cardiovascular functioning when it gets oxidized,” said Dr Yochi Hagay, the group’s chief technology officer (CTO) in a statement. “The unique composition of VINIA (that includes a complex of polyphenols with Piceid resveratrol) reduces the oxidation of the lipids as well as improves blood flow. These combined actions provide for an improved cardiovascular functioning. I believe that further clinical trials and research will prove additional important benefits of VINIA.”

READ: BioHarvest Sciences adds Steven Lehrer to its board of advisors

Ilan Sobel, BioHarvest CEO, added: “The unique functional capabilities of VINIA are creating a significant demand for VINIAacross the USA, similar to the demand we have been experiencing in Israel. These additional structure-function claims broaden the scope of benefits that VINIA brings to the US consumers and will raise further awareness for the brand and no doubt continue to increase growth momentum.”

BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself.

Contact the author at [email protected]

Story by ProactiveInvestors